Skip to main content
. Author manuscript; available in PMC: 2022 Oct 14.
Published in final edited form as: J Med Chem. 2021 Sep 17;64(19):14230–14246. doi: 10.1021/acs.jmedchem.1c00517

Figure 5.

Figure 5.

Cell viability and immunoprecipitation assays in RS4;11 with compound treatment in the presence or absence of VHL ligand VHL-032. (A) Viability of RS4;11 cells was determined after they were treated with DT2216, PP5, PZ703a, or PZ703b for 48 h with or without pre-treatment with VHL-032 (10 μM). Cell viability was measured using MTS assay. Data are representative of mean of three independent experiments performed in triplicates. (B,C) RS4;11 cells were treated with DT2216, PZ703b, ABT-263, or PZ703b-NC for 12 h with or without VHL-032. Immunoblots of Bim after immunoprecipitation with BCL-2 in the absence of VHL-032 (B) and in the presence of VHL-032 (C). (D,E) Bim, BCL-2, β-actin in whole-cell lysates (Input) are shown from two independent experiments.